

Traversing the pyramid: Data \rightarrow Information \rightarrow Knowledge \rightarrow Wisdom

Richa Sarin

Scientist, Analytical Development

Biogen



Putting Prior Knowledge to Immediate Use: Knowledge Management and Digital Tools to Accelerate Development

The Pyramid



Agenda

Overview & background

Vision

Case Studies

- Structured authoring: Recipe driven method development and qualification
- Data analytics: Optimizing the Clone Selection Process

Conclusion & Future Work

Acknowledgements



Overview



Challenges



Biogen.

Data challenges increase as you go up...



Data is our fundamental asset..

....We must utilize it to make informed decisions

But first...

....We need it to be easily accessible and consumable







To build a successful data management strategy, we must understand our processes, data inputs/outputs, and systems.

An established ontology is the foundation of any data strategy



Structured Authoring: Recipe Driven Development & Qualification (RDQ)



Opportunity



- Disparate experiment, data and reporting systems
- Lack of standardized approach to qualification
- No easy access to qualification data
- Manual execution of method steps







Vision: Recipe driven approach



Overview: Capillary Electrophoresis - Sodium Dodecyl Sulfate (CE-SDS)

• Purity & heterogeneity

• Separation based on molecular weight and hydrodynamic radius

Platform release method



The RDQ Framework



Impact of the RDQ framework

✓ This framework enables a systematic & standardized approach to qualification while optimizing user interaction and method execution

 Successful proof-of-concept with CE-SDS helped us realize efficiency gains of up to 66%



Monitor key attributes from multiple qualification experiments across multiple programs



Automated Report Generation







Utilizing data analytics to enable swift and informed decisions: Optimizing the Clone Selection process



Cell Line Development & Analytical Testing Strategy



- Sequence variants
- Glycoforms

- Post-translational modifications
- Charge variants
 - Purity & impurities

- Molecule-dependent
 - Cell line-dependent
- Process-dependent



Understanding and Mapping the Process



Historical Data for 4 mAbs were Analyzed



 $\frac{\text{Measures of Dispersion}}{\text{IQR} = Q_3 - Q_1}$ $\text{MADM} = median(|x_i - median(x)|)$ $\text{Standard Deviation } (\sigma)$ $\text{CV} = \frac{\sigma}{\mu}$

IQR correlated to MADM (R²>0.8) CV is scale invariant and skews high for sets with lower mean values

IQR, SD were used for analyses

- Assay data with higher IQR or SD indicate greater variability of the quality attribute (QA) tested (provided that assay itself has low variability)
- Higher variability QAs are valuable as they provide stronger differentiation of cell lines during screening



Assessment of Product Quality Results



OS 05

4

IQS

- Data from top 36 clones were analyzed from 4 mAbs
- Assays located in the top right quadrant (N-glycan, GXII charge variant) provide more data for clone rejection than those in the bottom left (e.g. SEC)

[®]Biogen.

10

Outcome

- ✓ Eliminated 2 of 6 assays needed to inform clone selection
- ✓ Enabled quicker selection of optimal clones
- Automate selection process III
- Predict top clones





Requires an ontology to sustain & scale

Conclusion

Process mapping and understanding is a key first step in establishing a data & knowledge management strategy

• Ontologies are critical in ensuring a sustainable or scalable strategy

 Agile and well scoped projects allow us to easily demonstrate value of harnessing our data, paving the way for an enterprise level initiative



Preparing for the Future

• Establish and apply an ontology across our drug development process

• Utilize our data to continue growing our process knowledge and understanding

• Apply the recipe driven approach to our analytical methods and other outputs

 Align with initiatives within industry (E.g.: Knowledge-aided Assessment and Structured Applications (KASA) led by the FDA, Industry 4.0)

Biogen.

Recipe-driven filings & marketing applications!

Acknowledgements

Biogen

Analytical Development

Maxime Usdin, Associate Scientist Naveed Hedayat, Associate Scientist Andy Blum, Scientist Devin Bailey, Associate Scientist Dr. Peter Bryngelson, Sr. Scientist Dr. Len Blackwell, Principal Scientist Dr. Lou Coury, Associate Director Dr. Bernice Yeung, Director Dr. Brian Fahie, Sr. Director

Cell Line Development

James Lambropoulos, *Sr Engineer I* Dr. Christina Alves, *Principal Scientist*

Global Process Analytics

Dr. Saly Romero-Torres, *Associate Director* Dr. Rob Guenard, *Sr. Director*

Regulatory Bem Atsma, Associate Director





THANK YOU!

QUESTIONS?



Biogen | Confidential and Proprietary



BACKUP



Biogen | Confidential and Proprietary



development & multiple programs enabling data-driven insights and decisions Cloud-based development of robust search capabilities enabling **easy accessibility** to data & **easy sharing** of data with our stakeholders (Quality etc.)



Modeling Philosophy

BIOPHARM MANUFACTURING >>

Modeling activities are tied to the knowledge continuum, hence just like knowledge, process models and applicability within (and outside) the automation architecture will evolve with time and experience.



Adapted from Dr. Ajaz S. Hussain, 5thEGA Symposium on Biosimilars, London

Biopharmaceutical Process Model Evolution- Enabling Process Knowledge Continuum from an Advanced Process Control Perspective Romero-Torres et.al. 31 American Pharmaceutical Review

Modeling Regulatory Expectations

FDA PAT Guidance

"Comprehensive statistical and risk analyses of the process are generally necessary to assess the reliability of predictive mathematical relationships. <u>Based on the estimated risk, a simple</u> <u>correlation function may need further support or justification,</u> <u>such as a mechanistic explanation of causal links among the</u> <u>process, material measurements, and target quality</u> <u>specifications."</u>

ICH Q11

"A scientifically justified model can enable a prediction of quality, and can be used to support the extrapolation of operating conditions across multiple scales and equipment."

USP 40 1039

"The underlying rationale for variable selection in chemometrics is twofold. First, certain predictor variables could be irrelevant to the intended purpose, and ideally, these variables should be minimized or removed from the model. For example, only specific wavelengths of the whole range generated by the spectrometer may bear information relevant to the variation in levels of the response variable. <u>Variable</u> selection for this purpose should be based on first principles and experience. Inclusion of unrelated predictors, such as irrelevant spectral regions, could potentially degrade performance of the model. A smaller number of variables from the preprocessed data can be used to achieve superior performance, such as accuracy, precision, and robustness."



 A data-driven approach alone (without any scientific knowledge) is not apt for process control or quality related decisions



Saly Romero-Torres et al.

Objectives



Establish..

templated platforms standardizing our practices **enabling faster cycle times** for new programs without compromising data quality (especially partner programs)



Enable..

easy accessibility to development and qualification data



Automate...

generation of qualification reports reducing analyst time by ~70%



execution of methods via automation tools promoting effective transfers to results generation



CE-SDS Qualification Workflow: Experiment Design and Execution





[•]Biogen Automation of reagent, sample prep & sample transfer reduced overall manual tasks by $\sim 50\%$